journal article·2026-08Open access

A multi-level charged micelle-based microneedle transdermal system for immunosuppressive tumor microenvironment regulation and synergistic therapy

Lijing Qin, Yongyi Bi, Xiu Wang, Tongjuan Liang, Wenzhong Li, Wanjun Liang

Abstract

T cells, and stimulates the secretion of pro-inflammatory factors (TNF-α and IFN-γ), demonstrating significant synergistic anti-tumor activity. Overall, this work establishes a highly efficient and safe transdermal co-delivery platform for the treatment of breast cancer. By leveraging synergistic immune activation mechanisms, it offers broad application prospects for breast cancer therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Photodynamic Therapy Research Studies · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (75)

Show source-provided references
1. A comprehensive strategy based on high clinical translational nanosystem for programmable immunotherapy of triple negative breast cancer10.1002/adma.202314309 ↗
2. Carrier-free procyanidin-ferric nanonetworks loading gefitinib to inhibit TMEM16A-EGFR mutual activation loop for photothermally enhanced breast cancer targeted therapy
3. TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak10.1016/j.ccell.2025.06.015 ↗
4. Targeted inhibition of MDSC-derived exosomal miR-155-5p restrains epithelial-mesenchymal transition in hormone receptor-positive breast cancer by regulating SIRT1
5. Anti-progestin therapy targets hallmarks of breast cancer risk10.1038/s41586-025-09684-7 ↗
6. Breast cancer exploits neural signaling pathways for bone-to-meninges metastasis10.1126/science.adh5548 ↗
7. The metastatic spread of breast cancer accelerates during sleep10.1038/s41586-022-04875-y ↗
8. Adipocyte-derived glutathione promotes obesity-related breast cancer by regulating the SCARB2-ARF1-mTORC1 complex10.1016/j.cmet.2024.09.013 ↗
9. Precise ratiometric drug delivery for the treatment of triple-negative breast cancer10.1021/acsnano.5c13083 ↗
10. Dual-organelle targeted photosensitizer with AIE characteristics for triple-negative breast cancer photodynamic therapy via apoptosis and immunogenic cell death
11. Advances in the management of endometrial cancer
12. Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy10.1186/s12943-025-02366-y ↗
13. Sodium butyrate enhances sorafenib-induced ferroptosis and immunogenic cell death by modulating IRF2-Oasl2-cGAS pathway in colorectal cancer
14. Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity10.1016/j.cell.2024.08.007 ↗
15. Peroxidase-inspired polyphthalocyanine networks with highly efficient sonocatalytic activities for on-demand tumor immunotherapies in breast cancers10.1021/acsnano.5c04490 ↗
16. Targeting immunogenic cell stress and death for cancer therapy10.1038/s41573-024-00920-9 ↗
17. Personalized vaccination of tumor-derived antigens and sting agonists for specific cancer immunotherapy
18. MALAT1 as a molecular driver of tumor progression, immune evasion, and resistance to therapy10.1186/s12943-025-02415-6 ↗
19. Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors10.1186/s12943-025-02352-4 ↗
20. Proteome instability is a therapeutic vulnerability in mismatch repair-deficient cancer10.1016/j.ccell.2020.01.011 ↗
21. Spatiotemporally controlled nanomicelles for synergistic phototherapy and immune reprogramming in triple-negative breast cancer10.1021/acsnano.5c09413 ↗
22. Tumour-derived microparticles obtained through microwave irradiation induce immunogenic cell death in lung adenocarcinoma10.1038/s41565-025-01922-3 ↗
23. Cellular senescence is immunogenic and promotes antitumor immunity10.1158/2159-8290.CD-22-0523 ↗
24. Polypeptide nanoformulation-induced immunogenic cell death and remission of immunosuppression for enhanced chemoimmunotherapy10.1016/j.scib.2020.07.013 ↗
25. Spatial regulation of cancer-associated fibroblasts and tumor cells via ph-responsive bispecific antibody delivery for enhanced chemo-immunotherapy synergy10.1021/acsnano.4c13277 ↗
26. Walking dead tumor cells for targeted drug delivery against lung metastasis of triple-negative breast cancer10.1002/adma.202205462 ↗
27. Empowering chemotherapy-induced antitumor immunity by multi-targeted synergistic combination nanomedicine for triple-negative breast cancer
28. Dual molecularly imprinted nanocomposite with transferrin mediated glioma targeting and cholesterol exhaustion for synergistic cuproptosis/immune checkpoint blockade/immunogenic cell death
29. A sodium alginate-based multifunctional nanoplatform for synergistic chemo-immunotherapy of hepatocellular carcinoma10.1002/adma.202301352 ↗
30. Smart design of targeted drug delivery system for precise drug delivery and visual treatment of brain gliomas10.1002/adhm.202402967 ↗
31. An in situ hydrogel-mediated chemo-immunometabolic cancer therapy10.1038/s41467-022-31579-8 ↗
32. Targeting triple-negative breast cancer using cord-blood CD34+ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity10.1186/s13045-025-01736-9 ↗
33. Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response10.1016/j.jhep.2025.03.035 ↗
34. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments10.1038/s41392-025-02325-5 ↗
35. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial10.1038/s41591-020-1044-8 ↗
36. Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial10.1038/s43018-024-00890-2 ↗
37. Glycosylation-driven programs coordinate immunoregulatory and pro-angiogenic functions of myeloid-derived suppressor cells10.1016/j.immuni.2025.04.027 ↗
38. Aberrant Notch-signaling promotes tumor angiogenesis in esophageal squamous-cell carcinoma10.1038/s41392-025-02309-5 ↗
39. Vascular normalization augments the antitumor efficacy of combined hdac inhibitor with immunotherapy in solid tumors10.1158/2159-8290.CD-24-1033 ↗
40. Arginase 1 drives mitochondrial cristae remodeling and PANoptosis in ischemia/hypoxia-induced vascular dysfunction10.1038/s41392-025-02255-2 ↗
41. Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis10.1186/s12943-025-02335-5 ↗
42. Tumour vasculature at single-cell resolution10.1038/s41586-024-07698-1 ↗
43. Highly bioactive mxene-m2-exosome nanocomposites promote angiogenic diabetic wound repair through reconstructing high glucose-derived immune inhibition10.1021/acsnano.3c09721 ↗
44. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?10.1126/science.1125950 ↗
45. MT-125 inhibits non-muscle myosin IIA and IIB and prolongs survival in glioblastoma10.1016/j.cell.2025.05.019 ↗
46. Sunitinib lipid nanoparticles remodel tumor vasculature to synergize with two-stage radiotherapy for enhanced radiosensitivity in breast Cancer10.1016/j.jconrel.2025.114406 ↗
47. Myeloid-derived suppressor cells in cancer and cancer therapy10.1038/s41571-023-00846-y ↗
48. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges10.1038/nrclinonc.2018.29 ↗
49. Phase II study of two weeks on, one week off sunitinib scheduling in patients with metastatic renal cell carcinoma10.1200/JCO.2017.77.1485 ↗
50. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma10.1056/NEJMoa1816714 ↗
51. Exosomal transfer of pro-pyroptotic miR-216a-5p exacerbates anthracycline cardiotoxicity through breast cancer-heart pathological crosstalk10.1038/s41392-025-02245-4 ↗
52. Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNFα–TRAF3–TAK1–MAPK axis10.1038/s41392-024-01977-z ↗
53. Sustained alternate-day fasting potentiates doxorubicin cardiotoxicity10.1016/j.cmet.2023.02.006 ↗
54. Nanomaterials with dual immunomodulatory functions for synergistic therapy of breast cancer brain metastases
55. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment10.1016/j.jconrel.2016.11.013 ↗
56. Discovering nanoparticle corona ligands for liver macrophage capture10.1038/s41565-025-01903-6 ↗
57. Designing lipid nanoparticles using a transformer-based neural network10.1038/s41565-025-01975-4 ↗
58. The innovative design of a delivery and real-time tracer system for anti-encephalitis drugs that can penetrate the blood-brain barrier10.1016/j.jconrel.2023.09.043 ↗
59. Immune cell targeting-mediated cytomimetic drug delivery system for BBB-penetrating and precise therapy of in situ glioma
60. Honokiol-magnolol-baicalin possesses synergistic anticancer potential and enhances the efficacy of anti-pd-1 immunotherapy in colorectal cancer by triggering gsdme-dependent pyroptosis
61. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors10.1186/s13045-023-01509-2 ↗
62. Advancing precision: a controllable self-synergistic nanoplatform initiating pyroptosis-based immunogenic cell death cascade for targeted tumor therapy10.1021/acsnano.3c09499 ↗
63. Light-triggered efficient sequential drug delivery of biomimetic nanosystem for multimodal chemo-, antiangiogenic, and anti-mdsc therapy in melanoma10.1002/adma.202106682 ↗
64. A piezoelectric-driven microneedle platform for skin disease therapy
65. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy10.1038/s41551-022-00989-w ↗
66. Quasi Fe MIL-53 nanozyme inducing ferroptosis and immunogenic cell death for cancer immunotherapy10.1038/s41467-025-57542-x ↗
67. AI-based classification of anticancer drugs reveals nucleolar condensation as a predictor of immunogenicity10.1186/s12943-024-02189-3 ↗
68. Splicing shift of RAC1 accelerates tumorigenesis and defines a potent therapeutic target in lung cancer
69. A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death10.1016/j.immuni.2024.04.025 ↗
70. Implanted microneedles loaded with sparfloxacin and zinc-manganese sulfide nanoparticles activates immunity for postoperative triple-negative breast cancer to prevent recurrence and metastasis10.1002/advs.202416270 ↗
71. IL-10 targets IRF transcription factors to suppress IFN and inflammatory response genes by epigenetic mechanisms10.1038/s41590-025-02137-3 ↗
72. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer10.1186/s12943-022-01515-x ↗
73. Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT110.1186/s12943-024-02124-6 ↗
74. Inverse oxide/alloy-structured nanozymes with nir-triggered enzymatic cascade regulation of ros homeostasis for efficient wound healing
75. Bioinspired ruthenium-manganese-oxygen complex for biocatalytic and radiosensitization therapies to eradicate primary and metastatic tumors10.1038/s41467-025-62999-x ↗